NASDAQ: ATAIAtaibeckley Inc Stock
$4.53-0.28 (-5.82%)
Updated Jun 3, 2026
ATAI Price
$4.53
Fair Value Price
-$0.00
Market Cap
$1.67B
52 Week Low
$2.00
52 Week High
$6.75
P/E
-1.61x
P/B
8.39x
P/S
362.71x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.49M
Earnings
-$663.40M
Gross Margin
100%
Operating Margin
-19,007.28%
Profit Margin
-19,019.4%
Debt to Equity
0.33
Operating Cash Flow
-$106M
Beta
1.43
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ATAI Overview
Atai Life Sciences N.V. is a clinical-stage biopharmaceutical company developing various therapeutic candidates that focus on various mental health disorders including depression, substance use disorder, and anxiety. The company's pipeline includes PCN-101, RL-007, DMX-1002, GRX-917, NN-101, VLS-01, EMP-01, RLS-01, DMX-1001, and others. Formerly known as Adripa Holding B.V., Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ATAI's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ATAI
Ranked#110 of 467
Ranked#110 of 467
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.93 | A | |
| $5.89 | A | |
| $279.00 | A |
Be the first to know about important ATAI news, forecast changes, insider trades & much more!
ATAI News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ATAI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ATAI ($4.53) is overvalued by 226,047.18% relative to our estimate of its Fair Value price of -$0.00 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ATAI ($4.53) is not significantly undervalued (226,047.18%) relative to our estimate of its Fair Value price of -$0.00 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ATAI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ATAI due diligence checks available for Premium users.
Valuation
ATAI fair value
Fair Value of ATAI stock based on Discounted Cash Flow (DCF)
Price
$4.53
Fair Value
-$0.00
Undervalued by
226,047.18%
ATAI ($4.53) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ATAI ($4.53) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ATAI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ATAI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.61x
Industry
17.66x
Market
24.47x
ATAI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8.39x
Industry
4.71x
ATAI is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ATAI's financial health
Profit margin
Revenue
$954.0k
Net Income
-$29.8M
Profit Margin
-3,121.8%
ATAI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ATAI's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$264.9M
Liabilities
$66.1M
Debt to equity
0.33
ATAI's short-term assets ($250.07M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATAI's short-term assets ($250.07M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATAI's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ATAI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$21.1M
Investing
-$21.7M
Financing
$821.0k
ATAI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ATAI vs Biotech Stocks
Ataibeckley Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.